JP Morgan Chase
CHRS icon

JP Morgan Chase’s Coherus Oncology CHRS Stock Holding History

JP Morgan Chase’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,600
Closed -$117K – 5782
2019
Q1 		$117K Buy
+8,600
New +$115K ﹤0.01% 4832
2018
Q4 		– Sell
-35,200
Closed -$581K – 5706
2018
Q3 		$581K Buy
+35,200
New +$624K ﹤0.01% 4212
2018
Q1 		– Sell
-22,500
Closed -$198K – 5402
2017
Q4 		$198K Hold
22,500
– – ﹤0.01% 4417
2017
Q3 		$304K Sell
22,500
-2,500
-10% -$33.1K ﹤0.01% 3981
2017
Q2 		$359K Hold
25,000
– – ﹤0.01% 3840
2017
Q1 		$529K Buy
+25,000
New +$615K ﹤0.01% 3684

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return